Cargando…

Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial

INTRODUCTION: Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ago, it was not investigated in accordance with current standards and so is no...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosso-Fernández, Clara, Sojo-Dorado, Jesús, Barriga, Angel, Lavín-Alconero, Lucía, Palacios, Zaira, López-Hernández, Inmaculada, Merino, Vicente, Camean, Manuel, Pascual, Alvaro, Rodríguez-Baño, Jesús
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2015
Materias:	Infectious Diseases
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386243/ https://www.ncbi.nlm.nih.gov/pubmed/25829373 http://dx.doi.org/10.1136/bmjopen-2014-007363

Ejemplares similares

Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to Enterobacteriaceae (SIMPLIFY): a study protocol for a multicentre, open-label, phase III randomised, controlled, non-inferiority clinical trial
por: López-Cortés, Luis Eduardo, et al.
Publicado: (2017)

Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial
por: Marín-Candón, Alicia, et al.
Publicado: (2021)

Opportunities for antibiotic optimisation and outcome improvement in patients with negative blood cultures: study protocol for a cluster-randomised crossover trial, the NO-BACT study
por: Jiménez-Jorge, Silvia, et al.
Publicado: (2019)

EUropean prospective cohort study on Enterobacteriaceae showing REsistance to CArbapenems (EURECA): a protocol of a European multicentre observational study
por: Gutiérrez-Gutiérrez, Belén, et al.
Publicado: (2017)

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections: A Randomized Clinical Trial
por: Sojo-Dorado, Jesús, et al.
Publicado: (2022)

Bacteraemic pneumonia caused by Neisseria meningitidis serogroup Y
por: Romero-Gomez, Maria Pilar, et al.
Publicado: (2011)

Synergistic activity of fosfomycin–meropenem and fosfomycin–colistin against carbapenem resistant Klebsiella pneumoniae: an in vitro evidence
por: Bakthavatchalam, Yamuna Devi, et al.
Publicado: (2020)

Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol
por: Anaya-Baz, Blanca, et al.
Publicado: (2020)

Randomised, open-label, non-inferiority clinical trial on the efficacy and safety of a 7-day vs 14-day course of antibiotic treatment for uncomplicated enterococcal bacteraemia: the INTENSE trial protocol
por: Maldonado, Natalia, et al.
Publicado: (2023)

Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: protocol of a multicentre, randomised, phase III trial
por: Shaw, E, et al.
Publicado: (2015)

Effect of Glycerol on Fosfomycin Activity against Escherichia coli
por: Ortiz-Padilla, Miriam, et al.
Publicado: (2022)

First bacteraemic human infection with Escherichia albertii
por: Inglis, T.J.J., et al.
Publicado: (2015)

Meropenem-Resistant Pandoraea Pneumonia in a Critically Ill Patient With COVID-19
por: Dlewati, Mohammad M, et al.
Publicado: (2021)

Plasma cfDNA predictors of established bacteraemic infection
por: Urosevic, Nadezda, et al.
Publicado: (2022)

Meropenem-Resistant Achromobacter xylosoxidans, Subspecies Denitrificans Bacteremia in a Patient With Stage IV Adenocarcinoma of the Lung
por: Agassi, Andre M, et al.
Publicado: (2021)

Detection of Low-Level Fosfomycin-Resistant Variants by Decreasing Glucose-6-Phosphate Concentration in Fosfomycin Susceptibility Determination
por: Martín-Gutiérrez, Guillermo, et al.
Publicado: (2020)

Comparison of prognostic factors between bacteraemic and non-bacteraemic critically ill immunocompetent patients in community-acquired severe pneumococcal pneumonia: a STREPTOGENE sub-study
por: Bellut, Hugo, et al.
Publicado: (2021)

In vitro Activity of Fosfomycin, Alone and Combined with Cefepime and Meropenem, Against Carbapenemase-Producing Gram-Negative Bacteria
por: Wiederhold, Nathan P, et al.
Publicado: (2017)

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
por: Shrief, Raghdaa, et al.
Publicado: (2022)

Quasiexperimental intervention study protocol to optimise the use of new antibiotics in Spain: the NEW_SAFE project
por: Palacios-Baena, Zaira R, et al.
Publicado: (2020)

Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR)
por: Gudiol, C, et al.
Publicado: (2017)

Non-inferiority trial of a shorter (7 days) compared with a longer (14 days) duration of antimicrobial therapy for the treatment of bacteraemic urinary sepsis, measured by microbiological success after the completion of therapy: a substudy protocol for the Bacteraemia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) multicentre randomised controlled trial
por: Rogers, Benjamin A, et al.
Publicado: (2023)

Biofilm formation is not associated with worse outcome in Acinetobacter baumannii bacteraemic pneumonia
por: Wang, Yung-Chih, et al.
Publicado: (2018)

Comparison of different sepsis scoring systems and pathways: qSOFA, SIRS, Shapiro criteria and CEC SEPSIS KILLS pathway in bacteraemic and non-bacteraemic patients presenting to the emergency department
por: Sparks, Rebecca, et al.
Publicado: (2022)

Antimicrobial Susceptibilities of Urinary Extended-spectrum β-lactamase Escherichia coli to Fosfomycin
por: Saeed, Nermin Kamal, et al.
Publicado: (2021)

Bacteraemic pneumococcal pneumonia and SARS-CoV-2 pneumonia: differences and similarities
por: Serrano Fernández, Leyre, et al.
Publicado: (2022)

Outcomes in Oxacillinases β-Lactamases (OXA-48) and New Delhi Metallo-β-Lactamase (NDM-1)-Producing, Carbapenem-Resistant Klebsiella Pneumoniae Isolates Obtained From Bloodstream Infections
por: Verma, Anuragani, et al.
Publicado: (2022)

Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing Klebsiella pneumoniae Clinical Strains
por: Cebrero-Cangueiro, Tania, et al.
Publicado: (2021)

Nitrofurantoin and Fosfomycin for Extended Spectrum Beta-lactamases Producing Escherichia coli and Klebsiella pneumoniae
por: Tulara, Neeraj Kumar
Publicado: (2018)

135 Fosfomycin Susceptibilities Among Uropathogenic Extended Spectrum Beta-Lactamase-producing Enterobacteriacea
por: Abbo, Lilian, et al.
Publicado: (2014)

In Vitro and In Vivo Synergism of Fosfomycin in Combination with Meropenem or Polymyxin B against KPC-2-Producing Klebsiella pneumoniae Clinical Isolates
por: Ribeiro, Aghata Cardoso da Silva, et al.
Publicado: (2023)

Multicentre, randomised, open-label, phase IV–III study to evaluate the efficacy of cloxacillin plus fosfomycin versus cloxacillin alone in adult patients with methicillin-susceptible Staphylococcus aureus bacteraemia: study protocol for the SAFO trial
por: Grillo, Sara, et al.
Publicado: (2021)

The first case of Francisella novicida infection in Taiwan: bacteraemic pneumonia in a haemodialysis adult
por: Jan, Hao-En, et al.
Publicado: (2022)

Clinical effectiveness and bacteriological eradication of three different Short-COurse antibiotic regimens and single-dose fosfomycin for uncomplicated lower Urinary Tract infections in adult women (SCOUT study): study protocol for a randomised clinical trial
por: Garcia-Sangenís, Ana, et al.
Publicado: (2021)

Virulence Profiles of Bacteremic Extended-Spectrum β-Lactamase-Producing Escherichia coli: Association with Epidemiological and Clinical Features
por: Rodríguez-Baño, Jesús, et al.
Publicado: (2012)

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol
por: Dickstein, Yaakov, et al.
Publicado: (2016)

Analysis of the challenges in implementing guidelines to prevent the spread of multidrug-resistant gram-negatives in Europe
por: Tacconelli, Evelina, et al.
Publicado: (2019)

Piperacillin–tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)
por: Bitterman, Roni, et al.
Publicado: (2021)

Efficacy and safety of early treatment with sarilumab in hospitalised adults with COVID-19 presenting cytokine release syndrome (SARICOR STUDY): protocol of a phase II, open-label, randomised, multicentre, controlled clinical trial
por: León López, Rafael, et al.
Publicado: (2020)

Study of Plasmid-Mediated Extended-Spectrum Beta-Lactamase-Producing Clinical Strains of Enterobacteriaceae From Tabuk Region
por: Alqahtani, Turki Mushabab T, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a0gmgr4r50qtdc78k08avgdvd5